News & Events > CDER Conversation: Evaluating the Risk of Drug-Drug Interactions

News & Events > CDER Conversation: Evaluating the Risk of Drug-Drug Interactions

The Division of Drug Information (DDI) - serving the public by providing information on human drug products and drug product regulation by FDA.

Talking with Issam Zineh, PharmD, MPH, FCP, FCCP, who is the director of the Office of Clinical Pharmacology, Office of Translational Sciences, CDER



All drugs inherently carry risks. During development, drug makers test their investigational drugs to identify risks and benefits, and work to minimize the risks – including those posed by drug-drug interactions. Still, major adverse drug interactions are preventable causes of morbidity and mortality. Issam Zineh, director of CDER’s Office of Clinical Pharmacology, further highlights how drug interactions affect patients, and how FDA addresses the issue.

For more information, please visit: Evaluating the Risk of Drug-Drug Interactions.